organization · Reporting owner
Oxford Science Enterprises plc
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Barinthus Biotherapeutics plc.
Report date September 09, 2026 · Filed September 11, 2026 · Amendment
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-09-09 · Other · Disposed 8,797,770 · Balance 0 F1: Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share. F2: Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.
F2: Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement.
PepGen Inc.
Report date September 30, 2025 · Filed October 01, 2025
Section 16 reporting ended · disclosed 2025-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,955,388 |
Reported balance
After 2025-09-30 transaction · row 1
1 source rowRow 1 · 2025-09-30 · Purchase · Acquired 200,000 · Balance 4,955,388 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 15:00 UTC Amendment | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | OtherOrdinary Shares | 8,797,770 | $0.11 | $976,552.47 |
DisclosureSEC source: 0001856079-26-000002 · primary_doc.xml · nonDerivative · entry 1 Oxford Science Enterprises plc · CIK 0001856079 · former 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share. F2 · price: Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 17:07 UTC | PepGen Inc. PEPG · Entity 6253 | PurchaseCommon Stock | 200,000 | $3.20 | $640,000.00 |
DisclosureSEC source: 0001856079-25-000003 · primary_doc.xml · nonDerivative · entry 1 Oxford Science Enterprises plc · CIK 0001856079 · Former 10% Owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,955,388 Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionSeries B Preferred stock · Derivative | 1,575,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · derivative · entry 6 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,547,713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionSeries A-2 Preferred stock · Derivative | 962,884 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · derivative · entry 5 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 945,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionSeries A-1 Preferred stock · Derivative | 1,285,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · derivative · entry 4 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,262,986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionCommon Stock | 1,547,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · nonDerivative · entry 3 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionCommon Stock | 945,859 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · nonDerivative · entry 2 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,327,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:42 UTC | PepGen Inc. PEPG · Entity 6253 | ConversionCommon Stock | 1,262,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017488 · doc4.xml · nonDerivative · entry 1 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,381,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date. Read SEC document |
| May 10, 2022 Filed Apr 9, 2024 21:24 UTC Amendment | PepGen Inc. PEPG · Entity 6253 | PurchaseCommon Stock | 879,970 | $12.00 | $10,559,640.00 |
DisclosureSEC source: 0000950170-24-043058 · ownership.xml · nonDerivative · entry 1 Oxford Science Enterprises plc · CIK 0001856079 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,755,388 Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionSeries B preferred shares · Derivative | 1,661,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 7 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,661,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionSeries A redeemable convertible preferred shares · Derivative | 1,704,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 6 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,704,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionOrdinary Shares · Derivative | 4,832,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 5 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,832,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | PurchaseAmerican Depositary Shares | 600,000 | $17.00 | $10,200,000.00 |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 4 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797,770 F2 · security: Each American Depositary Share represents one ordinary share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionOrdinary Shares | 1,661,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 3 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,197,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionOrdinary Shares | 1,704,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 2 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,536,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | ConversionOrdinary Shares | 4,832,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 1 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,832,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.